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Short-chain 3-hydroxyacyl-CoA dehydrogenase (SCHAD), encoded by the
HADH gene, is a ubiquitously expressed mitochondrial enzyme involved in
fatty acid oxidation. This protein also plays a role in insulin secretion as reces-
sive HADH mutations cause congenital hyperinsulinism of infancy (CHI) via
loss of an inhibitory interaction with glutamate dehydrogenase (GDH). Here,
we present a functional evaluation of 16 SCHAD missense variants identified
either in CHI patients or by high-throughput sequencing projects in various
populations. To avoid interactions with endogenously produced SCHAD pro-
tein, we assessed protein stability, subcellular localization, and GDH interac-
tion in a SCHAD knockout HEK293 cell line constructed by CRISPR-Cas9
methodology. We also established methods for efficient SCHAD expression
and purification in E. coli, and tested enzymatic activity of the variants. Our
analyses showed that rare variants of unknown significance identified in
populations generally had similar properties as normal SCHAD. How-
ever, the CHI-associated variants p.Gly34Arg, p.Ile184Phe, p.Pro258Leu,
and p.Gly303Ser were unstable with low protein levels detectable when
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expressed in HEK293 cells. Moreover, CHI variants p.Lys136Glu, p.His170Arg,
and p.Met188Val presented normal protein levels but displayed clearly
impaired enzymatic activity in vitro, and their interaction with GDH
appeared reduced. Our results suggest that pathogenic missense variants of
SCHAD either make the protein target of a post-translational quality control
system or can impair the function of SCHAD without influencing its steady-
state protein level. We did not find any evidence that rare SCHAD missense
variants observed only in the general population and not in CHI patients are
functionally affected.
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1 | INTRODUCTION
An increasing challenge of clinical medicine is how to han-
dle the wealth of information provided by high-throughput
genetic analyses. For a given patient, techniques such as
whole-exome and whole-genome sequencing may reveal
multiple, rare genetic variants that are of unknown signifi-
cance with regard to health implications.1 Predicting the
functional effect based on bioinformatics analyses alone is
still unreliable, particularly for missense mutations; that is,
when the genetic variant results in amino acid substitu-
tions at the protein level. This problem has, for example,
been illustrated by studies of HNF1A variants implicated in
monogenic diabetes.2
A concerted effort to functionally evaluate missense
variants of the HADH gene has so far not been
performed. This gene encodes short-chain 3-hydroxyacyl-
CoA dehydrogenase (SCHAD; EC 1.1.1.35), a mitochon-
drial protein expressed in all cells. It exerts a general
metabolic function by catalyzing the third step of
β-oxidation of short- and medium-chain fatty acids.3 In
addition, SCHAD has a specific role in glucose homeosta-
sis by inhibiting insulin secretion in the pancreatic
β-cells,4-7 most likely through an inhibitory effect on the
activity of another metabolic enzyme: glutamate dehy-
drogenase (GDH).8,9 Thus, a number of recessive muta-
tions in the HADH gene have been found to cause
congenital hyperinsulinism of infancy (CHI; OMIM #
609975).10-12 CHI is a disease characterized by inappro-
priately elevated plasma concentrations of insulin,
resulting in episodes of hypoglycemia that may become
life-threatening if not treated correctly.13,14
The gnomAD data set contains 155 HADH missense
variants, of which 154 are rare with an allele
frequency < 0.01.15 Only few of the SCHAD-CHI case
reports have examined protein expression and enzymatic
activity of the mutation in question.10,16,17 In addition, a
study of the C. elegans SCHAD protein experimentally
evaluated the structural and functional impact of two
amino acid substitutions in the conserved dimerization
interface of the protein.18
Here we have initiated a systematic assessment of
SCHAD amino acid substitutions by establishing a
toolkit of prokaryotic and eukaryotic expression vectors
for producing the protein variants as well as a SCHAD
knockout cell line for functional testing. We have
tested 16 naturally occurring missense variants for sta-
bility, subcellular localization, enzymatic activity and
GDH interaction. Overall, our data showed that
SCHAD variants reported in CHI patients display vari-
ous loss-of-function phenotypes, whereas functional
defects were not seen in any rare variant of the general
population.
2 | MATERIALS AND METHODS
2.1 | Plasmids
The complete coding sequence of the human HADH gene
(transcript variant 2, NCBI reference sequence
NM_005327.4) was synthesized (DNA 2.0) flanked by
sites for the restriction enzymes EcoRI and XhoI. For
eukaryotic SCHAD expression, the synthetic gene was
transferred to expression vector pcDNA3.1/V5-His B
(Invitrogen). The insert was cloned in-frame with the C-
terminal V5/His tag using EcoRI/XhoI and the Quick
Ligation Kit (NEB).
For prokaryotic expression, the synthetic gene served
as template to amplify HADH without the mitochondrial
import signal. Overhangs with BsmI and NcoI sites were
added in the 50-end and an Acc65I site in the 30-end. PCR




Fidelity PCR polymerase (Thermo Fisher Scientific) was
used with annealing at 53.2C for 20 seconds. The PCR
product was blunt-end-cloned into the vector pJet1.2
(CloneJET PCR Cloning Kit, Thermo Fisher Scientific).
Subsequently, the HADH insert of the pJet1.2 vector was
ligated to the pETM41-His/MBP expression vector in-
frame with an N-terminal 6His/Maltose Binding Protein
(MBP) tag (Quick Ligation Kit). Restriction enzymes
Acc65I/BsmBI were used for the insert and Acc65I/NcoI
for the vector.
Sixteen missense variants chosen from the gnomAD
data set15 (transcript ENST00000309522) and from CHI
case reports were introduced in the plasmids by using the
QuickChange II XL Site Directed Mutagenesis Kit
(Agilent). This kit was also used to delete the SCHAD
mitochondrial import signal (Δ2-12 construct). Primers
used to produce each variant are listed in Table S1.
The plasmid Plu-CMV-hGDH for over-expressing
human GDH was kindly provided by Dr Charles Stanley,
Philadelphia.
For propagation, all plasmids were heat shock-
transformed into One Shot TOP10 competent E. coli.
Plasmids were prepared by the QIAfilter Plasmid Midi
Kit (QIAGEN) and controlled by linearization/agarose
gel electrophoresis and Sanger sequencing.
Empty vector (EV) pcDNA3.1/V5-His B was used as
negative control in the expression studies. Theoretical
molecular masses were estimated using the ProtParam
tool on the ExPASy server.19 All sequence analyses for
site-directed mutagenesis and for CRISPR-Cas9 genome
editing (below) were performed by the SnapGene soft-
ware (GSL Biotech).
2.2 | Antibodies
To detect SCHAD protein by western blotting, different
polyclonal antibodies were used: rabbit anti-SCHAD
(Atlas Antibodies, HPA039588; GeneTex, GTX105167)
and goat anti-SCHAD (Novus Biologicals, NB100-77343).
A custom-made monoclonal mouse anti-SCHAD anti-
body (epitope QTEDILAKSK) from Abmart was
employed in some experiments. Mouse anti-V5
(R960-25), anti-mouse HRP conjugate (626520), anti-
rabbit HRP conjugate (656120), anti-mouse Alexa Fluor
488 conjugate (A-11017), and goat anti-GLUD1/2
(PA5-19267) were from Thermo Fisher Scientific. Rabbit
anti-β-tubulin (ab6046) and anti-β-catenin (ab32572)
were from Abcam. Mouse IgG2a (X0943) was
from DAKO.
2.3 | Establishment of a HEK293 SCHAD
knockout (KO) cell line by CRISPR-Cas9
The gRNAs 50-CACCGCACGGAACGCATGAACTGCC-
30 and 50-AAACGGCAGTTCATGCGTTCCGTGC-30,
targeting the sequence 50-CCAGGCAGTTCATGCG
TTCCGTG- 30 in the proximity of the HADH start codon
were designed via the website http://crispr.mit.edu. After
phosphorylation by T4 polynucleotide kinase, the gRNAs
were kept at 95C for 5 minutes, annealed by decreasing
the temperature to 25C (rate: 5C/min), ligated into the
pSpCas9(BB)-2A-Puro (PX459 v.2) plasmid (Addgene)
using BbsI sites, and transformed into One Shot TOP10
competent E. coli. Plasmid preparations were sequenced
using the primer 50-GAGGGCCTATTTCCCATGATT-30.
Human embryonic kidney (HEK293) cells (Clontech)
were transfected for 48 hours using the calcium phos-
phate method. Cells carrying plasmid were then selected
using 3 μg/mL puromycin in the growth medium for
96 hours. Surviving cells were detached with trypsin, and
single cells were hand-picked and transferred to individ-
ual wells in a 96-well plate. HADH exon 1 was sequenced
in surviving clones using the primers 50-
TCAACGCTGGGACGTTACA-30 and 50-GTGAAAACT
CCCTGGTGTCG-30. Finally, SCHAD expression in the
generated cell lines was evaluated by western blotting.
2.4 | HEK293 cell culture, SCHAD-V5
plasmid expression, western blotting
HEK293 cells (WT and SCHAD KO) were cultured in
DMEM medium supplemented with 10% FBS (Gibco)
and PenStrep (Sigma-Aldrich), and maintained in 5%
CO2 at 37C. Unless indicated otherwise, Lipofectamine
2000 (Thermo Fisher Scientific) was used for
transfection.
Treatment with the proteasome inhibitor MG132
(Sigma-Aldrich) was done 24 hours after transfection.
The culture medium was removed, and cells were incu-
bated with 5 μM MG132 or an equivalent volume of
DMSO in fresh medium for the specified amount of time.
To produce HEK293 whole-cell lysates, cells were
incubated in RIPA buffer (Thermo Fisher Scientific) and
centrifuged at 14 000g for 15 minutes at 4C to obtain a
clear supernatant. Protein concentration was measured
using the Pierce BCA protein assay kit (Thermo Fisher
Scientific).
For western blotting, the samples were mixed with
loading buffer and reducing agent, heated at 70C for
10 minutes and subjected to SDS-PAGE before transfer to
a PVDF membrane. The proteins of interest were
detected using specific antibodies and visualized by
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enhanced chemiluminescence using Amersham ECL
Prime Western Blotting detection reagent
(GE Healthcare) and a GBOX I Chemi XR5 imager
(Syngene).
2.5 | Cell-free expression of SCHAD-V5
plasmids
Cell-free expression of SCHAD variants was achieved by
incubating the pcDNA3.1-SCHAD-V5-His plasmids in
TNT T7 Quick Coupled Transcription/Translation master
mix (Promega). Each reaction was incubated for
90 minutes at 30C, and 3 μL were analyzed by western
blotting.
2.6 | Immunostaining and microscopy
HEK293 SCHAD KO cells were grown on poly-L-
lysine coated glass coverslips. To label the mitochon-
dria, cells were incubated for 30 minutes in 200 nM
MitoTracker Red CMXRos (Invitrogen) diluted in pre-
warmed cell medium. Cells were fixed for 15 minutes
with 4% paraformaldehyde, permeabilized with 0.2%
Triton X-100 in PBS and blocked with 1% BSA,
22.5 mg/mL glycine, 0.1% Tween in PBS. To stain for
SCHAD-V5, the cells were incubated consecutively
with the anti-V5 and anti-mouse Alexa Fluor 488 con-
jugate antibodies. Each incubation was 1 hour at room
temperature, with three PBS washes of 5 minutes in
between. Coverslips were mounted in ProLong Gold
Antifade Reagent with DAPI (Cell Signaling Technol-
ogy). The confocal images were collected using a TCS
SP5 confocal microscope with a 63×/1.4NA HCX Plan-
Apochromat oil immersion objective, ~1.0 airy unit
pinhole aperture, and appropriate filter combinations
(Leica Microsystems). Images were acquired with
405 diode, argon and DPSS 561 lasers and processed
using the LAS AF software.
2.7 | MBP-SCHAD protein expression
and purification
MBP-SCHAD plasmids were transformed into BL-21
(DE3) E. coli cells (NEB) by the heat shock method. A
single colony was inoculated and grown in LB medium
with 1% glucose and 50 μg/mL kanamycin at 37C. Pro-
tein expression was induced at OD600 = 0.6 by adding
0.1 mM IPTG. Bacteria were harvested after overnight
incubation at 22C and sonicated in a pH 7.8 buffer
(50 mM NaH2PO4, 500 mM NaCl, 10 mM imidazole,
0.1 mM DTT, 10% glycerol) complemented with
EDTA-free protease inhibitors (Roche). Recombinant
SCHAD protein was purified by immobilized metal
affinity chromatography (IMAC) on a HisTrap HP
5-mL column (GE Healthcare) followed by size exclu-
sion chromatography (SEC) on a Superdex
200 16/60120-mL column (GE Healthcare). Buffers
(pH 7.8) were as follows: IMAC wash buffer (50 mM
NaH2PO4, 300 mM NaCl, 20 mM imidazole, 0.1 mM
DTT, 10% glycerol), IMAC elution buffer (= wash
buffer with 250 mM imidazole), SEC buffer (50 mM
NaH2PO4, 150 mM NaCl, 0.1 mM DTT, 10% glycerol).
Fractions were analyzed by SDS-PAGE and
Coomassie staining (SimplyBlue SafeStain, Invi-
trogen) and protein concentration was determined by
A280 measurements.
2.8 | Multiangle light scattering
measurements
The molecular mass of MBP-SCHAD was calculated by
SEC-MALS using a Superdex 200 HR 10/30 column
coupled to a light-scattering device. Bovine serum albu-
min (BSA) was used as standard.
2.9 | SCHAD enzymatic assay
The enzymatic reaction was started by adding 0.07 μg of
purified MBP-SCHAD protein to 1.0 mL 100 mM potas-
sium phosphate buffer (pH 7.0) containing 0.1 mM DTT,
0.3 mg/mL BSA (fatty acid-free) and saturating concen-
trations of acetoacetyl-CoA (50 μM) and NADH
(0.15 mM). Absorbance at 340 nm was measured every
minute for 5 minutes at 37C.
2.10 | Co-immunoprecipitation (co-IP)
HEK 293 SCHAD KO cells seeded in 10-cm Petri dishes
were co-transfected with 2 μg Plu-CMV-hGDH and 6 μg
of pcDNA3.1-SCHAD-V5-His variants using the calcium
phosphate method. After 48 hours of transfection, cells
were washed with PBS, incubated for 10 minutes with
1 mM disuccinimidyl glutarate and quenched for
15 minutes with 50 mM Tris, pH 7.5. Immediately after,
co-IP was performed as follows (kit from Thermo Fisher
Scientific): 6 μg of antibody were coupled to 10 μL
AminoLink Plus Coupling resin, co-IP buffer was used
for cell lysis (500 μL/plate) and washing (×7), 450 μL of
cell lysate at 2.8 μg/μL were incubated for 1 hour with
the antibody-coupled-resin, and elution (×1) was by
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NuPAGE LDS Sample buffer (Thermo Fisher Scientific),
followed by western blotting.
2.11 | Statistical analysis
The software R20 with reshape221 and multcomp22 was
used. Plots were produced using the package ggplot2.23
To evaluate differences in the enzymatic activity of the
SCHAD variants, a one-way analysis of variance
(ANOVA) and a post-hoc Dunnett's test were used. To
evaluate differences in the amount of bound GDH, a one-
sample T-test was used.
3 | RESULTS
3.1 | Selection of SCHAD variants for
functional testing
To perform a systematic functional evaluation of SCHAD
protein variants, we chose 16 missense variants present
in human populations and CHI patients (Table 1). The
population variants were selected to be distributed
throughout the domains of SCHAD, and their positions
are illustrated in Figures 1A and S1A. Specifically, nine
variants were selected from the gnomAD data set,15 most
of them having an allele frequency in the range 0.0002 to
0.005 (Table 1). We also included p.Pro86Leu, which is
the most frequent SCHAD coding variant and the only
one with an allele frequency > 0.01.27 Additionally, seven
pathogenic variants found in CHI cases were included.
Of these, six have been described in case
reports10,16,17,24-26 whereas one, p.His170Arg, has been
identified in a CHI patient via our own clinical laboratory
service (unpublished).
To characterize functional aspects of these variants
in vitro, we introduced them by site-directed mutagenesis
into plasmids pcDNA3.1 (for expression in mammalian
cells as SCHAD-V5/His fusion protein) and
pETM41-His/MBP (for expression in E. coli as MBP-
SCHAD fusion protein).
3.2 | Expression of SCHAD missense
variants in HEK293 cells
SCHAD is a ubiquitous protein that occurs as homodimer
in its functional form.18,28 To avoid the interference that
dimerization with endogenous wildtype protein could
cause in cellular studies with exogenously expressed vari-
ants, we produced a HEK293 SCHAD KO cell line using
TABLE 1 Overview of HADH variants and the studied amino acid substitutions
Nucleotide changea Amino acid variantb Exon Reference SNP ID numberc Allele frequencyd Source
c.99C > G p.Ile33Met 1 rs74428123 0.00040 gnomAD
c.100G > C p.Gly34Arg 1 rs779135938 0.00001 24
c.171C > A p.Asp57Glu 2 rs137853102 0.00001 gnomAD
c.257C > T p.Pro86Leu 2 rs4956145 0.08480 gnomAD
c.275 T > G p.Phe92Cys 3 rs61735992 0.00568 gnomAD
c.406A > G p.Lys136Glu 3 rs1262186453 0.00003 25
c.456G > T p.Gln152His 4 rs1051519 0.00175 gnomAD
c.509A > G p.His170Arg 4 — — Unpublishede
c.550A > T p.Ile184Phe 5 — — 26
c.562A > G p.Met188Val 5 — — 16
c.614G > C p.Gly205Ala 5 rs144699575 0.00023 gnomAD
c.643C > A p.Pro215Thr 6 rs140413151 0.00184 gnomAD
c.662G > A p.Arg221His 6 rs76476980 0.00117 gnomAD
c.773C > T p.Pro258Leu 7 rs137853103 — 10
c.881A > G p.Asn294Ser 8 rs36030668 0.00235 gnomAD
c.907G > A p.Gly303Ser 8 rs201772964 0.00004 17
aAccording to NCBI reference sequence NM_005327.4.
bPredicted amino acid change. Notation according to NCBI reference sequence NP_005318.3.
cAccording to the Single Nucleotide Polymorphism Database (dbSNP) (https://www.ncbi.nlm.nih.gov).
dAccording to the gnomAD database (http://gnomad.broadinstitute.org).15
eUnpublished patient from own clinical laboratory service.
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CRISPR-Cas9 targeted genome editing. Disruption of
exon 1 of the HADH gene was verified through DNA
sequencing of selected colonies (Figure S2). Knockout at
the protein level was confirmed through western blotting
using different anti-SCHAD antibodies (Figure 1B). A
band of the expected molecular mass for SCHAD
(~34 kDa) was observed only for the lysates of HEK293
WT cells, and not for SCHAD KO cells.
We then tested expression of the SCHAD variants by
transiently transfecting the plasmids into HEK293
SCHAD KO cells. Figure 1C shows selected variants in
HEK293 SCHAD KO cells to summarize the most rele-
vant findings, whereas Figure S3 presents all 16 variants
expressed in both HEK293 WT and SCHAD KO cells.
Analysis of the cellular lysates by western blotting, using
an anti-V5 antibody (Figure 1C) or an anti-SCHAD anti-
body (Figure S3), revealed a band of the expected molec-
ular mass (~37 kDa) for the WT-V5/His fusion protein.
Most missense variants exhibited the same size and
expression levels as the WT protein. The five exceptions
were p.Gly34Arg, p.Phe92Cys, p.Ile184Phe, p.Pro258Leu,
and p.Gly303Ser. The p.Phe92Cys variant, found in the
gnomAD dataset, displayed slower electrophoretic mobil-
ity than the WT protein, but had the same expression
level. The four other variants, all CHI-associated, were
consistently expressed at reduced levels. This reduction
was more pronounced for p.Gly34Arg, p.Ile184Phe,
and p.Pro258Leu than for the p.Gly303Ser variant.
However, CHI variants p.Lys136Glu, p.His170Arg, and
p.Met188Val appeared similar to the WT protein and the
remaining population variants. All 16 variants yielded
the same expression pattern in normal HEK293 (WT) as
in the SCHAD KO cell line (Figure S3).
Next, we evaluated the expression and subcellular
localization of the variants by immunofluorescence of
transiently transfected KO cells. Figure 2 exemplifies
how variants exhibiting reduced protein levels in
Figure 1C, such as p.Pro258Leu and p.Gly303Ser, also
resulted in lower amounts of SCHAD-V5 when directly
visualized in the cells. Images of the other variants are
presented in Figure S4. For variants with lower protein
levels, we did not observe a uniform overall reduction in
SCHAD levels within the expressing cells. A few cells dis-
played a fluorescence pattern comparable to that of WT-
transfected cells, while most cells showed from very low
to undetectable SCHAD levels.
By confocal microscopy, we found that all variants
were correctly targeted to the mitochondria as shown by
co-localization of SCHAD-V5 with a mitochondrial-
specific stain (Figure S5).
FIGURE 1 Location of the studied missense variants in the SCHAD protein, construction of SCHAD-deficient HEK293 cells, and
expression of selected variants in these cells. A, SCHAD has three functional domains: the mitochondrial import signal (MIS; green), the
NAD-binding domain (blue) and the dimerization domain (yellow). Protein variants of unknown significance found in populations are in
black, while pathogenic variants found in CHI patients are displayed in red. Notation is according to the reference protein sequence
NP_005318.3. For simplicity, the prefix “p.” of the amino acid variants is not included in this and the other figures. B, Western blot of cell
lysates from HEK293 cells expressing (wildtype, WT) and not expressing (knockout, KO) SCHAD protein. Membranes were probed with two
different anti-SCHAD antibodies (#1, GeneTex; #2, Novus Biologicals). C, Western blot of whole-cell lysates of HEK293 SCHAD KO cells
transfected with the indicated variants. One μg of protein was loaded in each lane, and the SCHAD variants were detected with anti-V5
antibody. A representative image of three experiments is shown. An anti-β-tubulin antibody was used for monitoring the loading in B and
C. EV = empty vector
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3.3 | Translation and protein
degradation of SCHAD variants with
reduced protein levels
To further test expression of variants p.Gly34Arg,
p.Ile184Phe, p.Pro258Leu, and p.Gly303Ser, that is, those
displaying low protein levels in HEK293 cells, we used a
cell-free expression system. Equal amounts of the
plasmids were incubated with the cell-free expression
reaction mix followed by western blotting. In stark con-
trast to the results obtained with transfected cells, these
four variants now displayed similar protein levels to WT
SCHAD (Figure 3A). This confirmed that the plasmids
were fully functional with protein synthesis being as effi-
cient as from the WT plasmid. Moreover, this observation
hinted at the activity of a cellular quality control
FIGURE 2 Expression of selected
SCHAD variants in HEK293 SCHAD
KO cells as determined by
immunofluorescence. The cells were
transiently transfected with the
indicated V5-tagged SCHAD variants,
fixed 48 hours-post transfection, stained
using anti-V5 primary antibody and
fluorescent anti-mouse IgG secondary
antibody (green), and counterstained
with DAPI (blue). Images are
representative fields from two
experiments, each with two technical
replicates (×200). WT = wildtype,
EV = empty vector
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mechanism, not present in the cell-free expression system,
as explanation for the low variant levels in HEK293 cells.
To investigate whether the four variants were
degraded by the ubiquitin-proteasome system, we blocked
this pathway in transfected cells by using the proteasome
inhibitor MG132. Figure 3B demonstrates that the
variants p.Gly34Arg, p.Ile184Phe, and p.Pro258Leu
exhibited clearly increased protein levels after 24 hours of
MG132 treatment, suggesting that proteasomal degrada-
tion is of importance for their instability. There was also
a certain effect on the level of p.Gly303Ser, an increase
that was confirmed in two additional, independent
experiments.
3.4 | Enzymatic activity of purified
SCHAD variants
Although enzymatic activity of SCHAD can be measured
in cell and tissue lysates,3 we opted for using purified
protein due to the greater flexibility of the assay and full
control over the amount of SCHAD tested. Even though
we were able to express all variants in E. coli cells, the
purification efficiency differed considerably from variant
to variant (Figure S6 and data not shown). In fact, the
levels of p.Gly34Arg, p.Phe92Cys, and p.Ile184Phe were
undetectable at the end of the SEC purification step and
therefore no further work was performed on them. Nota-
bly, for all variants we employed a purification protocol
optimized for WT SCHAD. Thus, none of the conditions
were adjusted to the individual characteristics of any spe-
cific variant as an attempt to improve the yield.
We assessed the identity and purity of the samples by
SDS-PAGE, western blotting and Coomassie staining. For
all purified variants, a band around 75 kDa was detected
by anti-SCHAD (Figure 4A) and anti-His (data not
shown) antibodies. This agrees with the predicted molec-
ular mass of ~77 kDa for MBP-SCHAD. Coomassie
staining revealed a few additional, weak bands of higher
molecular mass and unknown identity in all cases
FIGURE 3 Expression of
unstable SCHAD variants in a
cell-free system and in HEK293
cells treated with a proteasome
inhibitor. A, Equal amounts of
the vectors expressing the
indicated variants were
incubated with the cell-free
expression master mix for
90 minutes. Three microliters of
each reaction were analyzed by
western blot using an anti-V5
antibody. WT = wildtype,
EV = empty vector. B, Twenty-
four hours after transfection
with the indicated variants,
HEK293 SCHAD KO cells were
treated with 5 μM MG132 or
only DMSO for the specified
times. To be able to visualize the
unstable variants, we loaded five
times the amount of whole-cell
lysate (5 μg) per well than
loaded in Figure 1C. The blots
were analyzed by anti-V5
antibody, whereas anti-β-tubulin
and anti-β-catenin antibodies
were used for monitoring the
loading and controlling the
efficiency of MG132 treatment,
respectively
VELASCO ET AL. 247
(Figure S7A). Some variants, most notably p.Ile33Met,
exhibited additional bands of lower molecular weight.
To test if recombinant MBP-SCHAD was purified in
the functional dimeric form, we estimated the molecular
mass of purified MBP-SCHAD WT by SEC-MALS
(Figure S7B). While the predicted monomeric molecular
mass was ~77 kDa, the calculated value by SEC-MALS
analysis was ~168 kDa. This indicated that MBP-SCHAD
WT was purified in the dimeric form. As the missense
variants all eluted at the same rate as WT SCHAD
(Figure S6), we expected them to be purified as
dimers, too.
Next, we assessed the enzymatic activity of the vari-
ants in saturating conditions of substrate and co-factor
(Vmax). MBP-SCHAD WT exhibited Vmax = 181
± 3 μmol/min/mg (Figure 4B). Variants found in patients
all showed reduced activity: p.His170Arg, p.Pro258Leu,
and p.Gly303Ser had severely reduced Vmax (<10 μmol/
min/mg), while p.Lys136Glu (127 ± 8 μmol/min/mg)
and p.Met188Val (132 ± 29 μmol/min/mg) displayed a
smaller, but still significant, reduction. Interestingly, the
population variant p.Pro215Thr had a slight increase in
enzymatic activity (211 ± 5 μmol/min/mg).
3.5 | Interaction of pathogenic SCHAD
variants with GDH
We were therefore left with principally two classes of
SCHAD pathogenic variants, one with severely reduced
cellular amounts of protein and another with impaired
enzymatic activity in the presence of normal protein
levels. The variants of the latter class might still have the
capacity to inhibit GDH, thereby carrying out normal
FIGURE 4 Purified recombinant
MBP-SCHAD variants from E. coli and
their enzymatic activity. A, Western blot
of all successfully purified variants.
Purified protein samples (0.3 μg) were
analyzed using the Abmart anti-SCHAD
antibody. B, The enzymatic activity of
the purified variants was tested on three
different days, each time with three
measurements. Each dot represents the
mean of a triplicate measurement and
the horizontal lines show the overall
mean. *P < .05, ***P < .001
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SCHAD function in insulin secretion. We therefore
evaluated the ability of the variants of the second class
(p.Lys136Glu, p.His170Arg, and p.Met188Val) to bind
GDH by using co-IP (Figures 5 and S8). We co-transfected
HEK293 SCHAD KO cells with GDH and the SCHAD
variant to be tested, and then treated the cells with a
crosslinking reagent before cell lysis and co-IP. This
ensured that we captured protein interactions within the
mitochondria. The set-up was validated by including a
SCHAD variant (Δ2-12) lacking the mitochondrial import
signal and therefore unable to locate with GDH inside the
mitochondria. The positive control (WT SCHAD) and all
negative controls (EV, Δ2-12, IgG) behaved as intended.
Somewhat unexpectedly, GDH was still able to co-IP with
the three pathogenic SCHAD variants (Figure 5A, B).
Nevertheless, the GDH levels were lower for the missense
variants than for WT SCHAD in eight of nine indepen-
dent Co-IPs tests performed (Figure 5C), although for
each variant the reduction did not quite reach statistical
significance when assessed separately.
4 | DISCUSSION
We here, for the first time, present a concerted functional
assessment of naturally occurring SCHAD missense vari-
ants. We have evaluated protein expression, intracellular
localization, enzymatic activity and GDH interaction. A
strength of our study is that we used a cell line devoid of
the SCHAD protein. Because this protein naturally forms
dimers,18,28 our approach allowed the functional testing
of SCHAD variants without the interference of endoge-
nous protein.
All tested SCHAD missense variants from verified
CHI patients displayed loss-of-function phenotypes. This
is in line with the other CHI mutations in the literature
being nonsense mutations, exon deletions or mutations
that affect the splicing machinery.11 Thus, pathogenic
HADH mutations are generally predicted to result in defi-
ciency of SCHAD protein. They are recessively inherited
in all reported pedigrees (eg, References 12 and 25). One
functional HADH allele therefore provides a level of
SCHAD protein function sufficient to avoid hypoglyce-
mic episodes, and dominant-negative mutations are yet
to be described.
We found altered properties for all seven CHI-
associated SCHAD variants examined. A few case
reports of missense mutations have investigated SCHAD
protein levels and/or enzyme activity in patient fibro-
blasts. Consistent with our findings, Clayton et al10 and
Vilarinho et al17 observed low protein levels for the vari-
ants p.Pro258Leu and p.Gly303Ser, respectively, whereas
Kapoor et al16 found decreased enzymatic activity for
p.Met188Val. However, while we noted a drastically
reduced Vmax for recombinantly expressed and purified
p.Gly303Ser, Vilarinho et al17 in patient fibroblasts
FIGURE 5 Co-immunoprecipitation of GDH with selected
SCHAD variants. A,B, HEK 293 SCHAD KO cells were co-
transfected with plasmids expressing GDH and selected SCHAD-V5
variants or with GDH and an empty plasmid vector (EV). The
SCHAD variant Δ2-12 lacked the mitochondrial import signal.
Forty-eight hours post transfection, cells were treated with a
crosslinking reagent before lysis. Cell lysates (450 μL) with equal
protein concentration (Input) were incubated with either V5 or IgG
antibodies coupled to agarose beads. The proteins bound to the
antibodies/beads (IP) were separated by SDS-PAGE, and SCHAD
(GeneTex antibody) and GDH were visualized by western
blotting. C, GDH and SCHAD western blot signals were quantified
for the variants and normalized to the WT sample. The dots
represent the calculated GDH/SCHAD ratio for each replicate with
the horizontal lines showing the mean for each variant. The dashed
line corresponds to the GDH/SCHAD ratio for the wildtype co-IP
reaction
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observed a Vmax comparable to the value of healthy
controls. Still, they noted that the enzymatic function
was affected by an increased Km for binding to the co-
factor NADH.
Our results suggest that SCHAD missense variants
causing CHI exhibit at least two types of loss-of-function
phenotypes. The first group, consisting of p.Gly34Arg,
p.Ile184Phe, p.Pro258Leu, and p.Gly303Ser, displays the
most common outcome for pathogenic missense muta-
tions; that is, a decrease of the protein's half-life leading
to lower amounts in the cell.29 This can be explained by
abnormal folding of the protein such that folding inter-
mediates and/or improperly folded proteins are degraded
through a protein-quality control system. Accordingly,
we readily achieved protein expression in a cell-free
eukaryotic system, and treatment with a proteasome
inhibitor stabilized the protein levels in HEK293 cells.
The small amounts of these variants still detectable by
western blot and immunofluorescence may represent a
fraction of the synthesized protein that managed to
obtain a folded state and escape degradation before
import to the mitochondria.30
A second loss-of-function phenotype was seen for CHI
variants p.Lys136Glu, p.His170Arg, and p.Met188Val.
Here, enzymatic activity of SCHAD was clearly impacted,
but without visible affection of steady-state protein levels.
It should be pointed out, though, that biophysical stress
(such as high temperature) might have demonstrated pro-
tein instability also in this group of missense variants.
Among all CHI variants studied, p.His170Arg was
the most atypical since it is the only one located
directly in the active site of the enzyme. The His170
residue is part of the catalytic His-Glu pair and func-
tions as a catalytic base, involved in proton abstraction
from the substrate.28 In the three-dimensional confor-
mation of SCHAD, p.Lys136 and p.Met188 are both
located on the surface of the NAD-binding domain,
opposite to the catalytic site (Figure S1B). Due to the
nature of these amino acids and their location, they
could be involved in some interaction or binding, criti-
cal for proper functioning of the protein. Notably, Xu
et al18 have demonstrated that mutations distant from
the catalytic site affect the enzymatic activity of
C. elegans SCHAD by decreasing the stability of the cat-
alytic intermediate formation. Considering that in the
context of insulin regulation, SCHAD acts by inhibiting
GDH,8 we tested this particular protein-protein interac-
tion, expecting that pathogenic variants with normal
steady-state protein levels would exhibit abolished
GDH binding. However, compared with WT SCHAD
we found only a partial reduction of the GDH interac-
tion. It is therefore not obvious how these three vari-
ants result in CHI.
Of the evaluated population variants, most had
properties like that of normal SCHAD. Intriguingly, the
p.Asp57Glu variant has been identified in a patient with
fulminant hepatic failure consistent with a metabolic
disorder involving defective fatty acid oxidation. The
patient was heterozygous for p.Asp57Glu, which
occurred together with the variant p.Ala40Thr.31 In fact,
a second variant in the Asp57 residue has been identi-
fied in a patient with Reye-like syndrome (p.Asp57Gly)
who was compound heterozygous, carrying another
unique variant, p.Tyr214His.32 Possibly, these variants
could affect the function of the SCHAD protein in fatty
acid oxidation but not in insulin secretion.
Among the population variants, p.Phe92Cys stood out
by consistently migrating with slower electrophoretic
mobility. Still, its protein level was as for WT SCHAD,
and we speculate that an extra post-translational modifi-
cation involving the Cys92 residue might cause the
apparent increase in molecular mass. As p.Phe92Cys was
the only population variant that could not be purified
after E. coli expression, we cannot rule out an effect on
enzymatic function. Still, with an allele frequency of
~0.006, this variant is the second most frequent SCHAD
amino acid substitution observed in populations, and we
consider it unlikely to have a pathogenic phenotype.
There is only one common variant (allele
frequency > 0.01) of the HADH gene that results in
change of protein sequence, namely p.Pro86Leu. When
expression levels and enzyme activity of p.Pro86Leu were
evaluated in fibroblasts of heterozygous carriers, proper-
ties comparable for non-carriers were found.27 Consider-
ing that around 0.7% of the population are predicted to
be homozygous for this SNP (based on allele frequency of
~0.085 according to the gnomAD database), it was inter-
esting to test the functional effects of this variant without
any interference of the WT protein. We observed no obvi-
ous difference regarding expression or enzymatic activity
when compared with normal SCHAD.
The phenotype of SCHAD deficiency is different from
that of other genetic disorders in which genes encoding
the enzymes of fatty acid oxidation are mutated. The pro-
tein has its highest expression level in the pancreatic
β-cells,5 and it is when the islet-specific function is
disrupted that hypoglycemia ensues.6 Notably, a recent
analysis of the genetic architecture of diabetes indicated a
small, protective effect of rare variants of the HADH gene
(Figure 2c in Reference 33), an effect that might be
explained by heterozygous carriers of rare HADH vari-
ants having increased capacity for insulin secretion. A
limitation of the present study is therefore that the amino
acid substitutions were not tested in cell lines that reflect
the β-cell environment, such as INS-1 or EndoC-βH1.
Hence, it is conceivable that a variant that in the present
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study appears normal with regard to SCHAD expression
and function, still could exhibit altered properties in β-cells.
Another limitation is that we included only one of the
four SCHAD variants found in patients who had no signs
of hyperinsulinism but presented with other metabolic
diseases (fulminant hepatic failure and Reye-like syn-
drome). Only the enzyme kinetics of these non-CHI vari-
ants have so far been investigated.31,32 It would have
been interesting to investigate their properties both indi-
vidually and in the combination that they appear in the
patients, comparing with the CHI-causing variants.
Finally, future studies should address whether the CHI
variants with normal protein levels are unable to inhibit
GDH despite being able to bind it, or whether these vari-
ants disturb other crucial interactions within the protein
super complex in which SCHAD is postulated to be
embedded.34 Investigations of how GDH kinetics and
protein complex formation are impacted by the normally
expressed variants may be needed to fully clarify the
mechanism of GDH activation in SCHAD-CHI.
Nevertheless, we have established a set of useful tools
for functional testing of SCHAD protein variants. This
toolkit includes a human cell line devoid of endogenous
SCHAD expression as well as a series of eukaryotic/pro-
karyotic expression plasmids with missense variants dis-
tributed over the two major protein domains. We found
no evidence that rare SCHAD amino acid substitutions
not seen in CHI patients exhibited impaired function.
This information will be of value when interpreting
HADH genetic variants revealed by high-throughput
sequencing projects and in clinical testing.
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